Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2713–2736 of 6,604 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Hepatitis C
Interventions: BZF961, Ritonavir, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: San Diego, California • Orlando, Florida • San Antonio, Texas

Conditions: Head and Neck Cancer Squamous Cell Carcinoma
Interventions: VS-101, Cisplatin, Radiation; Drug · Radiation
Lead sponsor: VSPharmTech Co.,Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: New Haven, Connecticut • Manhattan, New York

Conditions: Peripheral Diabetic Neuropathy, Painful Diabetic Neuropathy
Interventions: Capsaicin 8%; Drug
Lead sponsor: Averitas Pharma, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Wilmington, Delaware • Gainesville, Georgia • Jasper, Georgia + 7 more

Conditions: Primary Sclerosing Cholangitis
Interventions: Vancomycin, Placebo; Drug · Other
Lead sponsor: Elizabeth Carey; Other
Eligibility: 18 Years to 76 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Phoenix, Arizona • Tempe, Arizona • Jacksonville, Florida + 1 more

Conditions: Alzheimer's Disease
Interventions: Resveratrol with Glucose, and Malate, Placebo; Dietary Supplement
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 50 Years to 90 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab pegol; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 36
States / cities: Huntsville, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 33 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: GM604, Placebo comparator; Drug
Lead sponsor: Genervon Biopharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: MEDI4736 monotherapy, tremelimumab+MEDI4736; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Tampa, Florida • New York, New York

Conditions: Narcolepsy
Interventions: JNJ-17216498, Modafinil; Drug
Lead sponsor: Alza Corporation, DE, USA; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 16
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more

Conditions: Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer, Soft Tissue Sarcoma
Interventions: 68Ga-NNS309, 177Lu-DFC413; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Healthy
Interventions: LY3871801, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Cypress, California

Conditions: Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult, Liver Cell Carcinoma, Adult
Interventions: TKM-080301; Drug
Lead sponsor: Arbutus Biopharma Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Tucson, Arizona • San Francisco, California • Kansas City, Missouri + 2 more

Conditions: Schizophrenia
Interventions: PF-03463275, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 37
States / cities: Cerritos, California • Chula Vista, California • Escondido, California + 26 more

Conditions: Acute Lung Injury
Interventions: L-citrulline, Placebo; Drug · Other
Lead sponsor: Asklepion Pharmaceuticals, LLC; Industry
Eligibility: Up to 18 Years
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 20
States / cities: Birmingham, Alabama • Loma Linda, California • Sacramento, California + 16 more

Conditions: Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
Interventions: ECI830, ribociclib, fulvestrant; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Los Angeles, California • Fort Myers, Florida • Boston, Massachusetts + 5 more

Conditions: Congestive Heart Failure, Coronary Artery Disease, Myocardial Infarction
Interventions: MyoCell™, MyoCath™; Drug · Device
Lead sponsor: Bioheart, Inc.; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 5
States / cities: Sunrise, Florida • Atlanta, Georgia • Minneapolis, Minnesota + 2 more

Conditions: Actinic Keratoses
Interventions: PEP005 (ingenol mebutate) Gel, Vehicle gel; Drug
Lead sponsor: Peplin; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 17
States / cities: Hot Springs, Arizona • San Diego, California • Alpharetta, Georgia + 14 more

Conditions: Coronary Artery Disease
Interventions: IMPLELLA LP 2.5, IABP Intra-aortic balloon pump; Device
Lead sponsor: Abiomed Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 44
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 35 more

Conditions: Gastric Ulcer
Interventions: PN400 (VIMOVO), PN 400 (VIMOVO); Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Alzheimer's Disease
Interventions: CHF5074 1x, CHF5074 2x, CHF5074 3x, Placebo; Drug
Lead sponsor: CERESPIR; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Eatontown, New Jersey

Conditions: Allergic Conjunctivitis
Interventions: Ketotifen/naphazoline, Naphazoline, Ketotifen, Vehicle; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 6 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: North Andover, Massachusetts

Conditions: Brain Metastases
Interventions: Stereotactic Radiosurgery; Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Kidney Stone
Interventions: Moses Holmium:YAG laser, Thulium:YAG laser; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Phoenix, Arizona • New York, New York

Conditions: Anemia, Sickle Cell
Interventions: pomalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Search by objective public record fields.

Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients

Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer

Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy

Vancomycin for Primary Sclerosing Cholangitis

Randomized Trial of a Nutritional Supplement in Alzheimer's Disease

Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)

GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)

Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma

A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

A Study of LY3871801 in Healthy Asian and Non-Asian Participants

Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma

A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia

L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

MYOHEART™ (Myogenesis Heart Efficiency and Regeneration Trial)

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

Protect II, A Prospective, Multicenter Randomized Controlled Trial

A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)

Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.

Neurocognitive Decline in Patients With Brain Metastases

Prospective Multi-center Study Comparing Pulsed Tm:YAG Laser to Pulse Modulated Holmium Laser in the Treatment of Nephrolithiasis With FANS Access Sheaths

Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease